



(12) Translation of
European patent specification

(11) NO/EP 4108671 B1

NORWAY

(19) NO
(51) Int Cl.
C07H 19/10 (2006.01)
A61K 31/7115 (2006.01)
C07H 21/02 (2006.01)
C12N 15/11 (2006.01)

Norwegian Industrial Property Office

(45)	Translation Published	2025.02.03
(80)	Date of The European Patent Office Publication of the Granted Patent	2024.11.20
(86)	European Application Nr.	22173763.8
(86)	European Filing Date	2011.10.03
(87)	The European Application's Publication Date	2022.12.28
(30)	Priority	2010.10.01, US, 40441310 P
(84)	Designated Contracting States:	AL ; AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; RS ; SE ; SI ; SK ; SM ; TR
(62)	Divided application	EP3590949, 2011.10.03
(73)	Proprietor	ModernaTX, Inc., 325 Binney Street, Cambridge, MA 02142, USA
(72)	Inventor	Schrum, Jason P, Watertown, MA 02472-2580, USA Siddiqi, Suhaib, Burlington, MA 01803, USA Ejebe, Kenechi, New York, NY 10029, USA
(74)	Agent or Attorney	Budde Schou A/S, Dronningens Tværgade 30, 1302 KØBENHAVN K, Danmark

(54)	Title	MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF
(56)	References Cited:	WO-A2-2007/024708

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

Patentkrav

1. mRNA omfattende 1-metyl-pseudouridin for anvendelse som et medikament, hvori 100 % av nukleotidene omfattende uracil i mRNA-et erstattes med nukleotider omfattende N1-metyl-pseudouridin.
2. mRNA-et for anvendelse ifølge krav 1, hvori anvendelsen er for behandlingen eller forebyggingen av en sykdom eller tilstand i et pattedyr.
3. mRNA-et for anvendelse ifølge et hvilket som helst foregående krav, hvori anvendelsen er for behandlingen eller forebyggingen av en sykdom eller tilstand i et menneske.
4. mRNA-et for anvendelse ifølge et hvilket som helst foregående krav, hvori mRNA-et kan oppnås ved in vitro-transkripsjon, hvori de eneste NTP-ene anvendt for å fremstille mRNA-et i in vitro-transkripsjonen er N1-metyl-pseudouridintrifosfat, ATP, CTP og GTP.